MGC Pharmaceuticals - Dispatch of Annual General Meeting Documents

Argent BioPharma

31/10/2023 09:32

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231031:nRSe8613Ra&default-theme=true

RNS Number : 8613R  MGC Pharmaceuticals Limited  31 October 2023

 

MGC Pharmaceuticals Ltd.

Dispatch of Annual General Meeting Documents

31 October 2023

ASX, LSE: MXC

 

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') ) would like to advise
that it has dispatched the following documentation related to the Annual
General Meeting of shareholders to be held at 4:00pm (AWST) on Thursday, 30
November 2023 at Suite 1, 295 Rokeby Road, Subiaco Western Australia 6008, to
eligible shareholders.

A copy of which can be found at the following URL:
https://www.investi.com.au/api/announcements/mxc/aa4efb01-50f.pdf
(https://www.investi.com.au/api/announcements/mxc/aa4efb01-50f.pdf)

 

-Ends-

 

Authorised for release by the Managing Director, for further information
please contact:

 MGC Pharmaceuticals Ltd                                                  MGC Pharmaceuticals Ltd

 Roby Zomer                                                               Rowan Harland

 CEO & Managing Director                                                  Company Secretary

 +61 8 6555 2950                                                          +61 8 6555 2950

 info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)                       info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)
 UK IR/PR Advisers                                                        UK Brokers

 IFC Advisory                                                             Oberon Capital

 Graham Herring / Tim Metcalfe / Zach Cohen                               Aimee McCusker / Adam Pollock

 +44 203 934 6630                                                         +44 203 179 5300

 mgcpharma@investor-focus.co.uk (mailto:mgcpharma@investor-focus.co.uk)   aimeemccusker@oberoninvestments.com
                                                                          (mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
                                                                          (mailto:adampollock@oberoninvestments.com)

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
pharmaceutical company, focused on developing, manufacturing and supplying
accessible and ethically produced medicines, combining in-house research with
innovative technologies, with the goal of finding or producing treatments to
for unmet medical conditions.

 

The Company's founders and executives are key figures in the global
pharmaceuticals industry and the core business strategy is to develop and
supply high quality, innovative medicines for the growing demand in the
medical markets in Europe, North America and Australasia.

 

MGC Pharma has a robust development pipeline targeting two widespread medical
conditions and has further products under development.

 

MGC Pharma has partnered with renowned institutions and academia to optimise
the development and manufacturing of innovative medicines, to be produced in
the Company's EU-GMP Certified manufacturing facilities.

 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland
and has a global distribution footprint via an extensive network of commercial
partners meaning that it is poised to supply the global market.

 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAKFLBXXBLXFBB